AgomAb Therapeutics
ActiveSummary
AgomAb Therapeutics has been active since 2017 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €244.1m and a net result of -€9.6m. Equity grew by about 193% per year on average since 2018. In 2025 it fell by 3.8%. Its solvency ranks better than 95% of 892 sector peers (NACE 71, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Overview
Official details
Source: KBO- Status
- Active since 13-04-2017 Normal situation
- Registered office
- 10 active companies are registered at this address Source: KBO register, as of 5 November 2026.
- Activity
- Other technical testing and analysis NACE 71209and 2 others
- Joint committee
- 207 White-collar workers in the chemical industry · annual accounts 2022
- Establishment unit
- 2.268.629.862 2600 Antwerp, since 13-04-2017
- Financial year end
- 31 December
- Peppol
- Reachable since 05-03-2026
Board and ownership
- Auditor
- BV PwC Bedrijfsrevisoren
- Advent France Biotechnologydeed of 09-04-2019
- DE HAARD ANTIBODY TECHNOLOGIES B.V.deed of 09-04-2019
- EUREMAB SRLdeed of 09-04-2019
- Holdings
- Shares in 2 companies Agomab Spain SLU and Agomab US Inc.
Financial position
- Bankruptcy probabilitywithin 12 months
- < 0.1%
- Loss
- €9.6m
- ▼ 17.9%
- Equity
- €244.1m
- ▼ 3.8%
- Total assets
- €251.3m
- ▼ 2.8%
- Employees on 31-12-2025
- 53
- ▲ 1.9%
Score breakdownraises riskLoss of €9.6m, the second in a row (financial year 2025)lowers riskLiquidity: current ratio 39.79, cash €73.0mSector: Architectural and engineering activities; technical testing and analysis (NACE 71)Equity €244.1m (97.1% of total assets)Show the evidence
Checked score
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 71, medium-sized). It does better than 94% of them on solvency, 96% on liquidity, 11% on profitability and 27% on growth.
The bankruptcy probability was computed on 04-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 47 days before the deadline. In the sector (NACE 71), the median for financial year 2024 was 8 days before the deadline, and 34% of those companies filed late.
Searched, nothing found (2)
Key points
- Risk: 8 loss-making years in a rowloss in financial year 2025 -€9.6m View
- Caution: Lower net result than 95% of companies in architecture and engineeringsector median €35,976 · 894 companies -€9.6m View
- Subsidiary with negative equityAgomab Spain SLU · loss of €43.1m in 2025 -€109.0m View
- Board changedlatest change 11-09-2026 · 9 in office 2 joined · 1 left View
- Positive: Filed on time since financial year 2018accounts within the deadline every year 8 years View
- Flemish supportawarded from 2022 to 2025 €4.3m View
- Positive: More staff in 2025from 40.9 FTE to 52 FTE ▲ 27.1% View
Recent changes
- · Gazette deed Capital increase of €229,347.31 to €303,287,161.22Capital from €303,057,813.91 to €303,287,161.22, 210,170 new shares · Transfer of 210,170 shares from AgomAb Therapeutics
- · Gazette deed Appointments: Marino Garcia (non-executive director) and Naimish Patel (non-executive director)
- · Gazette deed Reappointments: Ohad Hammer (director) and Tim Knotnerus (director)
Companies linked to AgomAb Therapeutics
Comparable companies
These companies have the same main activity as AgomAb Therapeutics: other technical testing and analysis (NACE 71209). They are smaller than AgomAb Therapeutics: total assets between €47m and €97m, founded between 1994 and 2011.
| Company | Total assets | Turnover |
|---|---|---|
| AgomAb Therapeutics Antwerp | €251.3m | - |
| Wimble Services Belgium Mechelen | €46.9m | €32.1m |
| TS Holding Balen | €53.5m | €10.7m |
| IDEXX LABORATORIES Brussels | €51.1m | €19.6m |
| Ardena Gent Ghent | €58.8m | €26.7m |
| HENOGEN Charleroi | €97.2m | €48.7m |
| Federaal Agentschap voor Nucleaire Controle Brussels | €59.8m | €34.4m |
Key facts about AgomAb Therapeutics
- What is the company number of AgomAb Therapeutics?
- The company number of AgomAb Therapeutics is 0674.527.310. The VAT number is the same number with BE in front: BE 0674.527.310.
- Where is AgomAb Therapeutics based?
- The registered office is at Posthoflei 1, 2600 Antwerp.Company details
- What does AgomAb Therapeutics do?
- According to the KBO register, the main activity is other technical testing and analysis (NACE 71209).
- What is the legal form of AgomAb Therapeutics?
- AgomAb Therapeutics is a public limited company (NV).
- When was AgomAb Therapeutics founded?
- AgomAb Therapeutics was founded on 13-04-2017.
- Is AgomAb Therapeutics still active?
- Yes, AgomAb Therapeutics is an active enterprise in the KBO register.
- How many employees does AgomAb Therapeutics have?
- AgomAb Therapeutics had an average of 52 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does AgomAb Therapeutics fall under?
- In its 2022 annual accounts, AgomAb Therapeutics states joint committee 207 (White-collar workers in the chemical industry).
- What is the turnover of AgomAb Therapeutics?
- The annual accounts for financial year 2025 state no turnover.
- Is AgomAb Therapeutics profitable?
- In financial year 2025, AgomAb Therapeutics made a loss of €9.6m.
- Where can I find the annual accounts of AgomAb Therapeutics?
- AgomAb Therapeutics filed 9 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of AgomAb Therapeutics due?
- AgomAb Therapeutics must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.